TRIPODD Enables Single-Cell Quantification of Therapeutic Efficacy
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.5c01220 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Nathan P McMahon und 7 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Engineering, Illinois Institute of Technology, Chicago, Illinois 60616, United States. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Single-Cell Analysis. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Cancer Institute, Mark Foundation For Cancer Research.
Abstract (Originalsprache)
High Resolution Image Download MS PowerPoint Slide Targeted, small-molecule therapeutics have improved patient survival across cancer types, with >20 tyrosine kinase inhibitors (TKIs) receiving FDA approval as cancer therapies. While the initial TKI response is often promising, it is typically transient due to tumor evolution and subsequent therapeutic resistance driven by primary or acquired resistance mechanisms. While resistance mechanisms vary, there are currently no spatially resolved methodologies that provide a quantitative, mechanistic understanding of drug delivery and therapeutic response across therapeutic modalities (e.g., chemotherapy, radiotherapy, TKIs, immunotherapy) to enable personalized cancer therapy. Herein, we utilize our previously reported fluorescence imaging platform, T herapeutic R esponse I maging through P roteomic and O ptical D rug D istribution ( TRIPODD ), which is a quantitative protocol capable of interpreting the relationship between drug delivery and therapeutic response within the spatial context of a tumor to evaluate single-cell response and resistance to epidermal growth factor receptor TKI therapy. In this study, we applied TRIPODD to quantify the therapeutic response of EGFR-TKI-sensitive nonsmall cell lung cancer (NSCLC) xenografts to erlotinib, as a proof of concept for the platform. Through these studies, we were able to identify unique signatures of therapeutic response linked to the accumulation and engagement of erlotinib on a single-cell basis, demonstrating the utility of our TRIPODD platform technology in evaluating the treatment response and resistance at the single-cell level in heterogeneous tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biomedical Engineering, Illinois Institute of Technology, Chicago, Illinois 60616, United States.
ORCID-Profile: Kimberley S Samkoe, Lei G Wang, Summer L Gibbs
Förderung
- National Cancer Institute
- Mark Foundation For Cancer Research
Zitieren
APA
McMahon, N. P., Solanki, A., Montaño, A. R., Ozdemir, E. S., Samkoe, K. S., Tichauer, K. M., Wang, L. G., & Gibbs, S. L. (2026). TRIPODD Enables Single-Cell Quantification of Therapeutic Efficacy. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01220
Vancouver
McMahon NP, Solanki A, Montaño AR, Ozdemir ES, Samkoe KS, Tichauer KM, et al. TRIPODD Enables Single-Cell Quantification of Therapeutic Efficacy. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01220
BibTeX
@article{McMahon2026,
author = {McMahon, Nathan P and Solanki, Allison and Montaño, Antonio R and Ozdemir, E Sila and Samkoe, Kimberley S and Tichauer, Kenneth M and Wang, Lei G and Gibbs, Summer L},
title = {TRIPODD Enables Single-Cell Quantification of Therapeutic Efficacy},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.5c01220}
}
EUVIMED